All News

Article

FDA Approves IV Secukinumab

Jack Cush, MD Oct 10, 2023

On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Article

Surprising Link Between Weight Gain and RA Activity

MedPage Today Oct 10, 2023

In patients with rheumatoid arthritis (RA) treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.

JAKi Safety and Efficacy in bDMARD-IR Patients with RA View 5-year long-term extension outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. This poster is sponsored by AbbVie US Medical Affairs.https://t.co/Qr3KJXZJOe https://t.co/Ri1eS0q9Rb

Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequ…

Difficult #PMR Management Featuring Dr. Sebastian Sattui (Pittsburgh, PA) PMR with Difficulty Weaning plus Synovitis. QD Clinics are video vignettes with lessons from the clinic. https://t.co/dLYxwrmbJg @sattuiSEMD https://t.co/FDuHWJT7Ra

QD Clinic: Difficult PMR Management | RheumNow

PMR & Popeye's Spinach Dr. Jack Cush reviews the big #PMR reports from this week along with other journal reports from RheumNow. https://t.co/7oCQmuSATE https://t.co/5qWfZZzNBn

PMR & Popeye's Spinach (10.6.2023) | RheumNow

Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis #RA https://t.co/BhAKRXuzMY https://t.co/MqVHMieqiz https://t.co/zCvO2FbrZA

FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleuk…

Tuesday 10/10--this webinar focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew. https://t.co/4PefLrRoBx @drmaxyates1 @richardpaconway @drdavidliew https://t.co/089UBUsJLj

https://bit.ly/46LgLVz

Rheumatologist SURVEY Question: How often do you start a new PMR patient on 20mg or more of prednisone? Answer here>> https://t.co/beYWFwK1LX

Survey Result | RheumNow

Sustained Efficacy of Bimekizumab in PsA BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52. https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr

Sustained Efficacy of Bimekizumab in Psoriatic Arthritis | RheumNow

SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo). https://t.co/dC9Z7UgkcO https://t.co/44QEittlEX

SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica | RheumNow

2005 study of 364 PMR pts (age 73.4 yrs) - 284 Rx w/ steroids, predictors of relapse =higher initial CS dose & faster CS tapering. Relapse 4-fold higher when the CS tapering rate was fast (HR 4.27). Minimize initial CS dose and taper CS slowly!! https://t.co/hUpBO7fEgh https://t.co/fv9txM0BeH

Relapse in a population based cohort of patients with polymyalgia rheumatica.

Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm

Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19

Epidemiology of idiopathic inflammatory myopathies: - incidence 0.2 - 2 per 100,000 PYs - prevalence 2 - 25 per 100,000 #s vary w/ age/gender & geography; BUT is still unreported in South America, Africa & Asia https://t.co/fRUNV75xQL

New download on #PMR available now! https://t.co/esSuRBwSr0 https://t.co/7d2B2x63tF

PMR Slide Download #1 | RheumNow

Steroid Tapering in #PMR: What's the Gold Standard? Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica. https://t.co/oXVrHuHE58 https://t.co/fHNXodtAeV

Steroid Tapering in PMR: What's the Gold Standard? | RheumNow

1 in 3 of our pts are on steroids; nice ARD full read review of important papers on steroids 2022-23 written by Prof J Bijlsma, covering: Mechanisms of action CV AE Bone Effects Infections, COVID-19 Clin trials Benefit vs Harm Tapering GC Guidelines https://t.co/LnqLk8eKgn https://t.co/5xfvic5YIX

Annals of the Rheumatic Diseases collection on glucocorticoids (2020–2023): nov…

Pneumothorax in an RA patient is likely from rheumatoid nodules eroding into air spaces in advanced seropositive RA patients. https://t.co/u9rQlKKNKd https://t.co/QKquUngAld https://t.co/e9B3Jx92BW

FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu

This Tuesday Night Rheumatology focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew. https://t.co/swGbCcoEc9 @drmaxyates1 @richardpaconway @drdavidliew https://t.co/kZQ2wFbjt9

https://bit.ly/3F7TXDr

Topics

All News

FDA Approves IV Secukinumab

Surprising Link Between Weight Gain and RA Activity

Do you get our email newsletter?